Porton Advanced, Yinjia Biosciences Partner Up on CGTs
Joint venture revolves around around the use of raw materials for the development—and ultimately commercialization—of therapies.
Porton Advanced, a contract development and manufacturing organization (CDMO), has reached an agreement with Yinjia Biosciences, who is not only a raw material provider, but a company that offers diagnostics products for adjuvant therapies.
The deal aims to support development of core protein raw materials for cell and gene therapies (CGTs) and testing reagent products for quality control and evaluation systems to accelerate development and commercialization.
“We are glad to establish a strategic partnership with Yinjia Biosciences,” says Wang Yangzhou, PhD, CEO of Porton Advanced. “This strategic partnership will strengthen Porton Advanced’s CGT CDMO, and accelerate the development of innovative CGT therapeutics to deliver life-changing benefits to patients.”
Antares Vision Group, Siempharma Strike Up Pharma Labeling Equipment Collaboration
May 8th 2025The track-and-trace systems provider expands its life sciences portfolio by integrating the high-speed, adaptable ETF-300 precision labeler through a partnership that brings Industry 4.0-ready capabilities, advanced printing tech, and enhanced data security to pharmaceutical packaging.
